Active Biotech AB (0GQU)

Profile

https://www.activebiotech.com

Active Biotech AB (publ) is a Sweden-based biotechnology company headquartered in Lund, specializing in the research, development, production, marketing, and sales of medical, chemical, and biotechnology products. The company focuses on pharmaceutical innovations in areas where the immune system plays a critical role, particularly cancer and inflammatory eye diseases such as non-infectious uveitis. Its project portfolio features small, orally active immunomodulatory molecules and antibody-based immunotherapies, including tasquinimod for hematological malignancies like myelofibrosis and multiple myeloma in clinical phase Ib/IIa; laquinimod for inflammatory eye disorders, with ongoing clinical biodistribution studies for an eye drop formulation; and naptumomab estafenatox, licensed to NeoTX Therapeutics Ltd., advancing in phase Ib/II for solid tumors. Formed in 1998 as a spin-off from Pharmacia & Upjohn, Active Biotech leverages extensive expertise in drug development from early to late-stage clinical phases. With a competent team and a commitment to high medical need indications, it contributes to advancing treatments in oncology and ophthalmology through strategic partnerships and rigorous scientific evaluation.